Oleogel-S10 Phase 3 study "eASE" for epidermolysis bullosa: Study design and rationale

23Citations
Citations of this article
109Readers
Mendeley users who have this article in their library.

Abstract

Background: Epidermolysis bullosa (EB) is a group of rare, genetic diseases that affect the integrity of epithelial tissues, most notably the skin. Patients experience recurrent skin wounding, with severity depending on type, sub-type, and mutation. Oleogel-S10, a formulation of birch bark extract, has demonstrated efficacy in a Phase 2 trial assessing re-epithelialization of wounds in EB. EASE (NCT03068780, EudraCT 2016-002066-32) is a randomized, Phase 3, placebo-controlled study designed to determine the efficacy of Oleogel-S10 versus placebo in patients with EB. Methods: EASE is a Phase 3, two-phase study comprising a 90-day, double-blind, randomized, placebo-controlled phase, followed by 24 months of open-label, single-arm follow-up. Patients with junctional EB, dystrophic EB, or Kindler syndrome and target wounds (10 - 50cm2) present for > 21 days and < 9 months, are randomized in a 1:1 ratio to receive wound dressings according to local standard of care with or without Oleogel-S10. Placebo is based on the Oleogel-S10 vehicle, which is sunflower oil formulated to have a consistency indistinguishable from that of the active product. The primary endpoint of the trial, directed by the US health authority according to the required study endpoints for chronic cutaneous ulcer and burn wounds, is to compare the efficacy of Oleogel-S10 versus placebo according to the proportion of patients with complete closure of the target wound within 45 ± 7 days of treatment. Additional EB-focused endpoints include wound burden, patient-reported outcomes, and safety. Results: Results of the primary endpoint are anticipated to be available by H2 2019. Trial registration: ClinicalTrials.gov, NCT03068780. EudraCT, 2016-002066-32. Registered on 3 March 2017.

References Powered by Scopus

The Validity and Reproducibility of a Work Productivity and Activity Impairment Instrument

2323Citations
N/AReaders
Get full text

Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic disease

801Citations
N/AReaders
Get full text

Inherited epidermolysis bullosa: Updated recommendations on diagnosis and classification

724Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Investigational Treatments for Epidermolysis Bullosa

34Citations
N/AReaders
Get full text

Pharmacological Potential of Betulin as a Multitarget Compound

30Citations
N/AReaders
Get full text

Efficacy and safety of Oleogel-S10 (birch triterpenes) for epidermolysis bullosa: results from the phase III randomized double-blind phase of the EASE study

27Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Kern, J. S., Schwieger-Briel, A., Löwe, S., Sumeray, M., Davis, C., & Martinez, A. E. (2019). Oleogel-S10 Phase 3 study “eASE” for epidermolysis bullosa: Study design and rationale. Trials, 20(1). https://doi.org/10.1186/s13063-019-3362-z

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 24

57%

Researcher 10

24%

Professor / Associate Prof. 5

12%

Lecturer / Post doc 3

7%

Readers' Discipline

Tooltip

Medicine and Dentistry 20

44%

Nursing and Health Professions 15

33%

Pharmacology, Toxicology and Pharmaceut... 6

13%

Agricultural and Biological Sciences 4

9%

Article Metrics

Tooltip
Mentions
News Mentions: 3
Social Media
Shares, Likes & Comments: 50

Save time finding and organizing research with Mendeley

Sign up for free